CROMO-T, T cell therapy for cancer
| Reference number | |
| Coordinator | CarryGenes Therapeutivs AB - CarryGenes Therapeutivs |
| Funding from Vinnova | SEK 300 000 |
| Project duration | March 2019 - March 2020 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups step 1 spring 2019 |
Important results from the project
We aimed at creating a thorough basis for continued research and development of a chromosome therapy initially focusing on cancer. In achieving this goal, the company needed to create a strong financial platform. We reached the goal with a new share issue in December 2019, which created the necessary platform, i.e. the company´s stated purpose in the application.
Expected long term effects
A research company with employees, validating and develoingp the clinical product for the market launch. The company has now established a deep collaboration with American colleagues to secure the company and its therapy on the US market. Intensive research and development cooperation has been established. A professional board has been appointed to ensure competence and long-term vision.
Approach and implementation
The project was carried out according to the plan presented in the proposal. Vinnova´s grant helped the company to finance the preparation and implementation of a number of financing rounds, consulting costs and necessary analyses. The company dwells currently in the implementation phase of the development plans.